Illuminating biologics discovery with AI

Ailux Biologics partners with leading pharmaceutical and biotech companies to discover and develop best-in-class biologics. Dedicated AI solutions, every step of the way.

AI and humans excel at different tasks. We are pushing the limit of artificial intelligence in extracting hidden principles from large complex dataset, while leveraging our human creativity and expertise to make informed decisions.

Together, we aim to illuminate biologics discovery and to enable next-generation therapeutics that fill unmet patient needs.

A new chapter for biologics discovery

Biologics discovery is a journey with different challenges at every turn. We tailor a specific set of AI engines and wet lab tools to each challenge, recognizing that the discovery process is as unique as its goals.

Technology

Fully validated proprietary AI engines and wet lab methods to target the industry’s most challenging bottle necks

Three synergistic AI engines

Lorem ipsum dolor sit amet consectetur. Malesuada orci eleifend pharetra dui sit eget vel.

Explore our technology

Protein complex structure prediction to unlock limitless applications

Generative AI to explore extremely large sequence space

Predictive AI to evaluate and select best candidates

APPLICATION

Value-added applications to deliver highly differentiated biologics

How we deliver value

Hard targets

Next-gen engineering

Raise the bar

for conventional campaigns

PARTNERSHIP

Ailux collaborates with partners to tackle challenging targets and elevate lead candidates to the next stage of development

Partner with us

news & events

Explore our upcoming news & events

January 9, 2025

UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform

December 20, 2024

AET US 2024 | Trilux Antibody Discovery, Hit Expansion, and Affinity Modulation via Active Learning

November 21, 2024

PEGS Europe 2024 | AI-Powered Integrated Antibody Discovery and Multi-Objective Engineering

Together, let’s push the boundaries of medicine

The future of biotechnology is collaborative. We believe the best solutions come from working together with companies and researchers who share our vision. Are you ready to push the boundaries of what’s possible?

Partner with us

Case Study

Tapping into a greater search space for more quality hits using AI.

Immune Repertoire Analysis

In silico screening of millions of antibody sequences in the immune repertoire

K+

VL Clonotypes

K+

VH Clonotypes

Animals

NCS Datasets

M+

Unique VL Sequences

M+

Unique VH Sequences

Results and Insights

XploreSeq^TM Identifies Hits with High Accuracy

XploreSeq^TM routinely sequences millions of BCRs and identifies hits with high confidence (see figure). In this project, XploreSeq predicted 717 binders, from which 48 were randomly chosen for expression and testing. 66.7% (32/48) were confirmed to be binders, and only 18.6% (6/32) binders overlap with hybridoma hits.

Subscribe to our newsletter

Name(Required)

Work Email(Required)

Phone

This field is for validation purposes and should be left unchanged.

ab.bd@xtalpi.com

100 Chestnut Street, Somerville, MA 02143